Clinical Trials
38 trialsDaratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma
Mayo Clinic
Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant
National Cancer Institute (NCI)
²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
Fred Hutchinson Cancer Center
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
M.D. Anderson Cancer Center
Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
Thomas Jefferson University
Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma
City of Hope Medical Center
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
Thomas Jefferson University
Two Step Haplo With Radiation Conditioning
Thomas Jefferson University
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
National Institutes of Health Clinical Center (CC)
Personalized Autologous Transplant for Multiple Myeloma
Emory University
Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation
M.D. Anderson Cancer Center
HaploMUD-RIC
Institut Paoli-Calmettes
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
City of Hope Medical Center
Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma
Ohio State University Comprehensive Cancer Center
Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis
University of Utah
Autologous Transplant for Multiple Myeloma
Masonic Cancer Center, University of Minnesota
Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers
National Institutes of Health Clinical Center (CC)
Combined Haploidentical-Cord Blood Transplantation for Adults and Children
University of Chicago
Stem Cell Transplant for Hematological Malignancy
Masonic Cancer Center, University of Minnesota
Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies
Dartmouth-Hitchcock Medical Center
Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma
OHSU Knight Cancer Institute
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
Masonic Cancer Center, University of Minnesota
A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma
M.D. Anderson Cancer Center
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
M.D. Anderson Cancer Center
Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma.
H. Lee Moffitt Cancer Center and Research Institute
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
Washington University School of Medicine
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies
Washington University School of Medicine
Trial Of Double Umbilical Cord Blood Transplantation
University of Michigan Rogel Cancer Center
Microtransplantation Versus Auto-SCT in ≥PR Multiple Myeloma Patients
Beijing Chao Yang Hospital
S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
SWOG Cancer Research Network
Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)
Baylor College of Medicine
Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen
University of Michigan Rogel Cancer Center
Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma
M.D. Anderson Cancer Center
Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts
M.D. Anderson Cancer Center
Cellular Therapy With Cord Blood Cells
M.D. Anderson Cancer Center
Umbilical Cord Blood Stem Cell Transplantation in Adults With Advanced Blood Disorders or Cancer
Duke University
Non-Myeloablative Allogeneic Transplantation From Unrelated Donors in Multiple Myeloma
Azienda Ospedaliera San Giovanni Battista